Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer



Status:Archived
Conditions:Breast Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:December 2009
End Date:December 2011

Use our guide to learn which trials are right for you!

Phase I/II Trial of Amrubicin as Second- or Third-Line Treatment for Patients With HER2-Negative Metastatic Breast Cancer


Doxorubicin has been an integral part of the treatment of women with breast cancer for many
years. Since amrubicin may have more activity than doxorubicin, as well as less
cardiotoxicity, evaluation of amrubicin in the treatment of advanced breast cancer should be
a priority. In this Phase II study, the investigators propose an evaluation of single-agent
amrubicin as second- or third-line treatment for women with metastatic breast cancer.


This will be a phase I/II study where phase I will evaluate the maximum tolerated dose of
amrubicin, and phase II will assess the progression free survival of patients with
HER2-negative metastatic breast cancer using the dose established in the phase I portion.


We found this trial at
3
sites
250 25th Ave N, Ste 100
Nashville, Tennessee 37023
615-320-5090
Tennessee Oncology, PLLC Since 1976 Tennessee Oncology has been providing quality cancer care. In 2013,...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
3840 Broadway
Fort Myers, Florida 33901
(239) 275-6400
?
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Gainesville, Florida 30501
?
mi
from
Gainesville, FL
Click here to add this to my saved trials